Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice or a recommendation for any specific genetic test. Discuss whether pharmacogenomic or other genetic testing is appropriate for your care with a qualified psychiatric provider.
What Is Psychiatric Genetic Testing?
Genetic testing in psychiatry refers to laboratory-based analysis of a patient’s DNA to inform clinical decision-making. The most clinically utilized form today is pharmacogenomics (PGx) — testing that examines how genetic variants affect the way a person metabolizes, responds to, or tolerates psychiatric medications. A growing but still-emerging application is neuropsychiatric genetic panels, which screen for variants associated with conditions like ASD, ADHD, intellectual disability, and epilepsy.
This is one of the fastest-evolving areas in all of medicine. Understanding what these tests can — and cannot — do is essential for patients and families navigating psychiatric care.
How Pharmacogenomics Works
Most psychiatric medications are metabolized by enzymes in the liver, primarily from the cytochrome P450 (CYP450) family — including CYP2D6, CYP2C19, CYP3A4, and others. Genetic variants in these enzymes determine whether a person is a:
- Poor metabolizer — the enzyme functions slowly or not at all; standard doses may accumulate to toxic levels
- Intermediate metabolizer — reduced enzyme activity; may need lower doses
- Normal (extensive) metabolizer — expected response to standard doses
- Ultrarapid metabolizer — enzyme works faster than normal; standard doses may be ineffective as the drug is cleared too quickly
Commonly tested genes include CYP2D6 (affects metabolism of many antidepressants and antipsychotics), CYP2C19 (SSRIs like citalopram and escitalopram), and SLC6A4 (serotonin transporter gene, linked to SSRI response). The MTHFR gene variant — which affects folate metabolism and neurotransmitter synthesis — is also frequently included and has implications for treatment-resistant depression.
Clinically Recognized Applications
Medication Selection
When multiple medications are options, PGx results can help prioritize those likely to be metabolized normally and flag those with elevated risk of toxicity or subtherapeutic levels due to your metabolizer status.
Dose Optimization
Poor and ultrarapid metabolizers may require significantly different doses than standard guidelines suggest. PGx can guide dose adjustments before — not after — a trial-and-error period.
Treatment-Resistant Cases
When patients have failed multiple adequate medication trials, genetic testing may uncover metabolic explanations — such as ultrarapid CYP2D6 status — that were never previously considered.
Neurodevelopmental Evaluation
Chromosomal microarray and targeted gene panels are a standard part of evaluation for children with ASD, intellectual disability, or developmental delay — identifying clinically actionable variants in roughly 15–20% of cases.
Important context: Pharmacogenomic testing tells you about metabolism — how your body processes a drug. It does not predict whether a medication will work for your diagnosis, or whether you will experience every possible side effect. It is one clinical input among many.
Facts & Myths
Genetic testing in psychiatry is surrounded by both hype and misunderstanding. Here is a direct comparison of common claims versus the clinical reality:
| ✘ Myth |  Fact |
|---|---|
| Myth: A genetic test can tell you exactly which psychiatric medication will work best for you. | Fact: PGx identifies how you metabolize medications — not whether they will be therapeutically effective for your condition. No test currently predicts antidepressant or antipsychotic efficacy with reliability. |
| Myth: If a test says a medication is “green” (normal metabolism), it will definitely work and be well-tolerated. | Fact: “Green” means expected metabolism — not guaranteed efficacy or freedom from side effects. Pharmacodynamic factors (receptor sensitivity, brain chemistry) are not captured by current PGx panels. |
| Myth: Genetic testing can diagnose ADHD, depression, or autism. | Fact: No genetic test diagnoses psychiatric conditions. Psychiatric diagnoses are clinical — based on history, symptoms, and functional impairment — not genetic markers. Genetic panels support evaluation but do not replace it. |
| Myth: MTHFR gene variants are a major psychiatric condition requiring treatment in everyone who carries them. | Fact: MTHFR variants (C677T, A1298C) are extremely common — present in 30–60% of the population. Most carriers have no clinical problem. MTHFR is clinically relevant primarily in treatment-resistant depression, where L-methylfolate supplementation may help. |
| Myth: Genetic results don’t change with time, so one test is enough forever. | Fact: Your underlying DNA does not change, but the clinical interpretation of variants evolves as research advances. A result from five years ago may be reinterpreted in light of new evidence. Panels themselves also expand over time. |
| Myth: Consumer direct-to-consumer (DTC) genetic tests like 23andMe are equivalent to clinical pharmacogenomic testing. | Fact: DTC tests are not validated for clinical decision-making in psychiatry. They cover different variants, use different methodologies, and lack the clinical interpretation and provider oversight required for safe medication management. |
| Myth: Insurance never covers psychiatric genetic testing. | Fact: Coverage has expanded significantly. Many major insurers cover PGx testing for patients with documented treatment-resistant depression or other qualifying criteria. Medicare has specific coverage provisions. Prior authorization requirements vary widely. |
What to Expect From Testing
Clinical PGx testing typically involves a cheek swab or blood sample and returns results in 5–10 business days. Results are provided in a clinical report categorizing relevant genes and medications by metabolizer status, with prescribing guidance. The most widely used panels in psychiatry include tests from GeneSight (Myriad), Genomind, and OneOme RightMed — each covering overlapping but distinct gene sets.
Testing is most useful when ordered and interpreted by a clinician who understands both the possibilities and limitations of the results. Raw genetic data without clinical interpretation is of limited — and potentially misleading — value.
Privacy Protections
Patients often worry about genetic data privacy. The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from discriminating based on genetic information. However, GINA does not cover life, disability, or long-term care insurance. Clinical genetic test results ordered by a provider are part of your protected health record under HIPAA and are not shared with insurers without your authorization.
Crisis Resources: Call or text 988 | Text HOME to 741741 | Call 911 for emergencies.
Further reading: CPIC Guidelines — cpicpgx.org | PharmGKB — pharmgkb.org | ACMG Genetic Testing Resources — acmg.net
Pharmacogenomic Testing at Ascent Psychiatry
Dr. Modan incorporates genetic testing into complex medication evaluations when clinically indicated — interpreting results in the full context of your history, diagnosis, and treatment goals.